Galapagos NV

Latest Results (13.10.2025):

In the second quarter of 2025, Galapagos NV announced significant leadership changes and strategic initiatives aimed at enhancing shareholder value and expanding its pipeline. The company reported a strong cash position of €3.1 billion, despite an increased operating loss influenced by strategic reorganization efforts. Galapagos remains focused on advancing its cell therapy programs and evaluating potential divestitures to optimize its business portfolio.

Leadership Appointments

Galapagos NV has strengthened its executive team with the appointment of Henry Gosebruch as CEO and Aaron Cox as CFO, alongside seasoned business development leaders Sooin Kwon and Dan Grossman. These changes are designed to drive strategic transactions and pipeline growth.

Strategic Review of Cell Therapy Business

The company is evaluating strategic alternatives for its cell therapy division, including a potential divestiture. Galapagos Cell Therapeutics has been established as a standalone entity to consolidate all cell therapy activities, with updates expected in the third quarter of 2025.

Strong Cash Position

As of June 30, 2025, Galapagos NV maintained a robust cash and financial investments balance of €3.1 billion, providing a solid foundation for future growth and business development initiatives.

Advances in Cell Therapy Pipeline

Galapagos presented promising clinical data for its CAR-T programs, including GLPG5101, which showed high efficacy and a favorable safety profile in treating non-Hodgkin lymphoma. The company is progressing towards pivotal development and has established a collaboration for decentralized manufacturing of GLPG5101.

Financial Performance Overview

For the first half of 2025, Galapagos reported total net revenues of €140.3 million, unchanged from the previous year. However, the operating loss increased to €215.7 million, primarily due to strategic reorganization costs. Research and development expenses surged by 91% to €278.0 million, reflecting the company's investment in its pipeline.